-
Clinical or Utilization Outcomes Associated with the use of the MONARCH™ Platform in Diagnostic or Therapeutic Bronchoscopy
|
Johnson and Johnson MedTech Surgery, is interested in receiving proposals for investigating the clinical usage of the MONARCH™ Platform and outcomes in diagnostic or therapeutic bronchoscopy when used as indicated.
|
4/8/2025
|
-
Clinical outcomes associated with the use ETHIZIA™ Hemostatic Sealing Patch for soft tissue bleeding during cardiovascular surgical procedures (EMEA/AsiaPac).
|
ETHICON, Inc. is interested in receiving proposals investigating ETHIZIA™ Hemostatic Sealing Patch (herein ETHIZIA) when used as an adjunct to control bleeding from soft tissue during open or minimally invasive cardiovascular surgical procedures.
|
9/22/2025
|
-
Clinical outcomes associated with the use ETHIZIA™ Hemostatic Sealing Patch to achieve hemostasis during open or minimally invasive surgery (EMEA/AsiaPac)
|
ETHICON, Inc. is interested in receiving proposals investigating the use of the ETHIZIA™ Hemostatic Sealing Patch (herein ETHIZIA) when used as an adjunct to control bleeding during open or minimally invasive surgeries. Use of ETHIZIA on cardiovascular or neurological tissue is excluded.
|
9/22/2025
|
-
Clinical outcomes associated with the use STRATAFIX™ Spiral Monocryl™ Plus Unidirectional/Bidirectional for wound closure in cardio-thoracic, orthopedic (including joint/spine/trauma), general surgery and OB-GYN procedures. These procedures can be either laparoscopic, open or robotic with a special interest in robotic procedures.
|
ETHICON, Inc. is interested in receiving proposals for investigating the use of the STRATAFIX™ Knotless Tissue Control Device for use in soft tissue approximation where the use of absorbable sutures is appropriate.
|
1/16/2025
|
-
Funding opportunity for research involving the use of Megadyne products.
|
ETHICON, Inc. is interested in receiving proposals for research involving Megadyne products.
|
5/11/2022
|
-
Research and publication examining the prevention and treatment of dysphagia in patients who have received the LINX™ Reflux Management System.
|
A commonly reported adverse event captured after the implant of the LINX™ Reflux Management system is post-operative dysphagia. Although dysphagia is a known adverse event and included in the IFU, it continues to be a frequently reported after implantation of the LINX™ Reflux Management system. Dysphagia is also an adverse event frequently associated with explant of the device.
As such, Johnson & Johnson MedTech Surgery is interested in receiving proposals for research summarizing the best practices for both the prevention and treatment of dysphagia in patients who have received the LINX™ Management System.
|
4/28/2026
|
Just a moment, the page is loading...